文章基本信息

标题：Low Copper and Brain Abnormalities in Fetus from Triethylene Tetramine Dihydrochloride-Treated Pregnant Mouse
本地全文：下载
作者：Harumi TANAKA ; Masahiro YAMANOUCHI ; Shoji IMAI 等
期刊名称：Journal of Nutritional Science and Vitaminology
印刷版ISSN：0301-4800
电子版ISSN：1881-7742
出版年度：1992
卷号：38
期号：6
页码：545-554
DOI：10.3177/jnsv.38.545
出版社：Center for Academic Publications Japan
摘要：The effects of prenatal triethylene tetramine dihydrochlo-ride (Trien-2HCl) exposure on fetal mice have been investigated on gestational day 19. Trien-2HCl was given throughout pregnancy at levels of 0 (control), 3, 000, 6, 000, or 12, 000ppm as drinking water, ad libitum. At the level of 12, 000ppm, the frequency of total resorption tended to be high and that of fetal viability tended to be low, as compared to controls. Decreased maternal weight was observed in body, but not in liver, at the level of 12, 000ppm. Fetal body and cerebrum weights significantly decreased at the levels of 6, 000 and 12, 000 ppm; however, fetal liver weight remained unchanged. Maternal serum copper concentration was not affected by the Trien-2HCl. Fetal copper concentrations of liver and cerebrum were significantly lower in the Trien-2HCl-treated groups than in the controls, with levels decreasing in a dose-related manner. When the copper and zinc concentrations in the group treated at 12, 000ppm were compared with those in controls, significant decreases in both metals were observed in placenta but not in maternal liver. Changes in fetal zinc concentration varied by tissues: i, e. , an increase in liver and no change in cerebrum. Fetal abnormalities were frequently observed in brain, and the frequency was increased with increasing levels of the Trien-2HCl. These results suggest that fetal brain abnormalities caused by Trien-2HC1 may be due in part to induction of copper deficiency, which is almost equivalent to that in brindled mutant mouse.
关键词：triethylene tetramine dihydrochloride;copper deficiency;zinc;fetal mouse;pregnancy;brain abnormality;Menkes kinky-hair disease;Wilson's disease;copper-chelating drug